MicroRNA expression profile in patients with cystic echinococcosis and identification of possible cellular pathways

Abstract Cystic echinococcosis (CE) is a neglected tropical disease, caused by metacestode (larval) form of the Echinococcus granulosus sensu lato (sl) in humans. MicroRNAs (miRNAs) are small, stable, tissue-specific RNA molecules encoded by the genome that are not translated into proteins. Circulating miRNA expression profiles vary in health and disease. The aim of this study is to determine the altered cellular pathways in CE by comparing the miRNA profiles of controls and CE patients with active or inactive cysts. Following abdominal ultrasonography (US) examination, 20 patients diagnosed with active CE (CE1, CE2, CE3a and CE3b) or inactive CE (CE4 and CE5) and three healthy controls were included in the study. The expression profiles of 372 biologically relevant human miRNAs were investigated in serum samples from CE patients and healthy controls with miScript miRNA HC PCR Array. Compared with the control group, expression of 6 miRNAs (hsa-miR-4659a-5p, hsa-miR-4518, hsa-miR-3977, hsa-miR-4692, hsa-miR-181b-3p, hsa-miR-4491) and one miRNA (hsa-miR-4687-5p) were found to be downregulated in CE patients with active and inactive cysts, respectively (p < 0.05). For downregulated miRNAs in this study, predicted targets were found to be associated mainly with cell proliferation, apoptosis, cell-cell interactions and cell cycle regulation. Further studies in this direction may elucidate the pathogenesis of human CE and the relationship between CE and other pathologies.

Download Full-text

Evidence for potential involvement of pro-inflammatory adipokines in the pathogenesis of idiopathic intracranial hypertension

Cephalalgia ◽

10.1177/0333102416650705 ◽

2016 ◽

Vol 37 (6) ◽

pp. 525-531 ◽

Cited By ~ 10

Author(s):

Bedia Samancı ◽

Yavuz Samancı ◽

Erdem Tüzün ◽

Güneş Altıokka-Uzun ◽

Esme Ekizoğlu ◽

...

Keyword(s):

Intracranial Hypertension ◽

Idiopathic Intracranial Hypertension ◽

Oligoclonal Bands ◽

Enzyme Linked Immunosorbent Assay ◽

Control Group ◽

Healthy Controls ◽

Childbearing Age ◽

Serum Samples ◽

Necrosis Factor Alpha ◽

Tnf Α

Background Although specific role players are currently unknown, contribution of inflammatory mediators has been suggested in the pathophysiology of idiopathic intracranial hypertension (IIH), which is a disease more prevalent in obese female individuals of childbearing age. We aimed to investigate the levels of adipokines and cytokines to demonstrate possible markers for inflammation that participate in IIH pathophysiology and their association with clinical features of IIH. Methods IIH patients, diagnosed according to the revised criteria, and age-, gender- and body mass index (BMI)-matched healthy controls were enrolled in this study. Serum samples were evaluated for insulin-like growth factor 1, insulin, nesfatin, adiponectin, interleukin (IL)-1β, IL-6, IL-8, leptin, plasminogen activator inhibitor type-1, resistin, tumour necrosis factor-alpha (TNF-α) and monocyte chemotactic protein 1 via enzyme-linked immunosorbent assay or multiplex immunoassays. Results IL-1β level was significantly higher ( p = 0.012), and IL-8 and TNF-α levels were significantly lower in the IIH group ( p < 0.001 and p = 0.008, respectively) compared to the control group. There were no correlations between the cytokine/adipokine levels and age, BMI, disease duration, and cerebrospinal fluid oligoclonal bands. There were also no significant differences in cytokine and adipokine levels between IIH patients regarding visual impairment. However, statistically significant differences were found between IIH patients with relapse versus healthy controls regarding IL-1β ( p = 0.007), IL-8 ( p = 0.001) and TNF-α ( p = 0.017) levels. Other investigated cytokines and adipokines showed no significant alterations in IIH patients investigated in the remission period. Conclusion Altered serum levels of IL-1β, IL-8 and TNF-α seem to be associated with IIH pathogenesis, and these cytokines may be used as prognostic markers in IIH to predict relapse.

Download Full-text

Cytokine expression profiles of patients with acute myelogenous leukemia (AML) and non-Hodgkin lymphoma (NHL) detected by multiplex assay

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.18530 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 18530-18530

Author(s):

V. B. Reddy ◽

D. K. Oelschlager ◽

J. S. Nolan ◽

K. L. Taylor ◽

J. Post ◽

...

Keyword(s):

Expression Profiles ◽

Recovery Phase ◽

Cytokine Expression ◽

Multiplex Assay ◽

Myelogenous Leukemia ◽

Control Group ◽

Serum Samples ◽

Expression Levels ◽

Significant Difference ◽

Low Levels

18530 Background: To determine the cytokine expression profiles of patients with AML and NHL using a sensitive bead-based Luminex multiplex assay in a routine clinical diagnostic setting. Methods: Blood (plasma/serum) samples were collected from ten AML and five NHL patients. Six control samples from patients diagnosed as non-neoplastic/non-autoimmune/non-inflammatory were also analyzed for comparison. All samples were frozen prior to analysis. Using a bead-based Luminex assay (Human Cytokine 8-Plex Assay, Bio- Rad, Hercules, CA) we analyzed these samples for a panel of cytokines (IL-2, IL-4, IL-6, IL-10, GM-CSF, IFN-gamma, and TNF-alpha). This assay uses polystyrene microspheres, which provides simultaneous quantitation of these cytokines in a single sample. The expression levels were presented in picograms/mL. Average values for each of these markers were obtained for each group of patients (AML versus NHL versus Controls), and their expression levels were compared using χ2 analysis. Results: Overall, there was a significant difference in the expression profiles of all these cytokines among three patients groups (χ2, P < 0.001). All cytokines were consistently expressed at low levels in NHL patients as compared to control group. However, the levels of IL-6 and IL-8 were increased by 2.7 and 5.8 times, respectively in AML patients as compared to controls. Conclusions: The low levels of cytokines in NHL and AML patients suggest suppressed immune system in these two disease conditions; however, these findings warrant further studies to explore the underlying mechanisms for the increased levels of IL-6 and IL-8 in AML patients. Currently, studies are in progress to compare the levels of cytokines measured by Luminiex assay in different stages of leukemias and lymphomas (initial, post treatment and recovery phase etc.). These studies are partially funded by grants from the National Institute of Health/National Cancer Institute (RO1-CA98932–01 and U24-CA086359). No significant financial relationships to disclose.

Download Full-text

The Role of MicroRNAs (miRNA 155, miRNA-146b) and Procalcitonin as Novel Markers for the Diagnosis of Spontaneous Bacterial Peritonitis

The Open Biomarkers Journal ◽

10.2174/1875318302111010028 ◽

2021 ◽

Vol 11 (1) ◽

pp. 28-38

Author(s):

Dalia M. A. El-Hassib ◽

Dina M. Abo-elmatty ◽

Noha M. Mesbah ◽

Sherief Abd-Elsalam ◽

Shorouk A. Bastawisy ◽

...

Keyword(s):

Spontaneous Bacterial Peritonitis ◽

Quantitative Polymerase Chain Reaction ◽

Serum Levels ◽

Serum Marker ◽

Control Group ◽

Serum Samples ◽

Rna Molecules ◽

Bacterial Peritonitis ◽

Infection And Inflammation

Background: MircoRNAs are endogenous, small non-coding RNA molecules that have been recognized as important modulators of gene expression. MicroRNA is considered one of the potential biomarkers of infection and inflammation. Our study aims to identify the potential role of miRNA-155, miRNA-146b, and Procalcitonin (PCT) in the early detection of spontaneous bacterial peritonitis in cirrhotic liver patients. miRNA-155 and 146b are molecular biomarkers , while procalcitonin is a serum marker in ascites patients complicated with Spontaneous Bacterial Peritonitis (SBP) . Methods: This study was conducted on 199 patients, 101 of them have ascites complicated with spontaneous bacterial peritonitis, and 98 patients without spontaneous bacterial peritonitis (control group). Ascitic fluid samples were collected from patients with SBP undergoing paracentesis at National Hepatology Institute in Egypt. MicroRNAs were determined in the serum using qPCR (quantitative polymerase chain reaction), while procalcitonin has been assessed in serum samples using ELISA (Enzyme-linked immune assay) technique. Results: Serum levels of miRNA-146b & miRNA-155 were significantly higher (p<0.001) in spontaneous bacterial peritonitis patients (79.2% and 97.0% respectively) than ascites patients (17.3% and 7.1%, respectively). Furthermore, the serum level of procalcitonin was significantly higher (p<0.001) in spontaneous bacterial peritonitis patients than that in ascites patients (68.3% and 27.6%, respectively). Conclusion: miRNA-155, miRNA-146b and procalcitonin can be used as early markers for the detection of SBP in hepatic patients with ascites.

Download Full-text

Serum Metabolites as an Indicator of Developing Gestational Diabetes Mellitus Later in the Pregnancy: A Prospective Cohort of a Chinese Population

Journal of Diabetes Research ◽

10.1155/2021/8885954 ◽

2021 ◽

Vol 2021 ◽

pp. 1-13

Author(s):

Mengyuan Tian ◽

Shujuan Ma ◽

Yiping You ◽

Sisi Long ◽

Jiayue Zhang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Early Pregnancy ◽

Pantothenic Acid ◽

Maternal Serum ◽

Control Group ◽

Healthy Controls ◽

Serum Samples ◽

Serum Metabolites

Objective. Gestational diabetes mellitus (GDM) is a common metabolic disorder with onset during pregnancy. However, the etiology and pathogenesis of GDM have not been fully elucidated. In this study, we used a metabolomics approach to investigate the relationship between maternal serum metabolites and GDM in early pregnancy. Methods. A nested case-control study was performed. To establish an early pregnancy cohort, pregnant women in early pregnancy ( 10 ‐ 13 + 6 weeks) were recruited. In total, 51 patients with GDM and 51 healthy controls were included. Serum samples were analyzed using an untargeted high-performance liquid chromatography mass spectrometry metabolomics approach. The relationships between metabolites and GDM were analyzed by an orthogonal partial least-squares discriminant analysis. Differential metabolites were evaluated using a KEGG pathway analysis. Results. A total of 44 differential metabolites were identified between GDM cases and healthy controls during early pregnancy. Of these, 26 significant metabolites were obtained in early pregnancy after false discovery rate ( FDR < 0.1 ) correction. In the GDM group, the levels of L-pyroglutamic acid, L-glutamic acid, phenylacetic acid, pantothenic acid, and xanthine were significantly higher and the levels of 1,5-anhydro-D-glucitol, calcitriol, and 4-oxoproline were significantly lower than those in the control group. These metabolites were involved in multiple metabolic pathways, including those for amino acid, carbohydrate, lipid, energy, nucleotide, cofactor, and vitamin metabolism. Conclusions. We identified significant differentially expressed metabolites associated with the risk of GDM, providing insight into the mechanisms underlying GDM in early pregnancy and candidate predictive markers.

Download Full-text

Metabolomic Characterization of Acute Ischemic Stroke Facilitates Metabolomic Biomarker Discovery

10.21203/rs.3.rs-661365/v1 ◽

2021 ◽

Author(s):

Biao Qi ◽

Yanyu Zhang ◽

Yuhao Zhang ◽

Guoqiang Fei ◽

Ling lin ◽

...

Keyword(s):

Ischemic Stroke ◽

Acute Ischemic Stroke ◽

Biomarker Discovery ◽

Multiple Reaction Monitoring ◽

Control Group ◽

Healthy Controls ◽

Serum Samples ◽

Multivariate Statistical ◽

Lysine Degradation

Abstract Acute ischemic stroke (AIS) is characterized by a sudden blockage of one of the main arteries supplying blood to the brain, leading to insufficient oxygen and nutrients for brain cells to function properly. Unfortunately, metabolic alterations in the biofluids with AIS are still not well understood. In this study, we performed high-throughput target metabolic analysis on 44 serum samples, including 22 from AIS patients and 22 from healthy controls. Multiple reaction monitoring analysis of 180 common metabolites revealed a total of 29 metabolites changed significantly (VIP>1, P <0.05). Multivariate statistical analysis unraveled a strikingly separation between AIS patients and healthy controls. Comparing AIS with Control group, the contents of argininosuccinic acid, beta-D-glucosamine, glycerophosphocholine, L-abrine, and L-pipecolic acid were down-regulated in AIS patients. 29 out of 112 detected metabolites, enriched in aminoacyl-tRNA biosynthesis, glycerophospholipid metabolism, lysine degradation, phenylalanine, tyrosine and tryptophan biosynthesis metabolic pathways. Collectively, these results will provide a sensitive, feasible diagnostic prospect for AIS patients.

Download Full-text

Detection of specific IgG, IgM, IgE and IgG subclass antibodies for serological diagnosis of human cystic echinococcosis

Helminthologia ◽

10.1515/helmin-2015-0016 ◽

2015 ◽

Vol 52 (2) ◽

pp. 85-88 ◽

Cited By ~ 1

Author(s):

M. I. Naik ◽

R. Kumar Tenguria ◽

Ehtishamul Haq

Keyword(s):

Cystic Echinococcosis ◽

Diagnostic Sensitivity ◽

Antibody Detection ◽

Enzyme Linked Immunosorbent Assay ◽

Parasitic Infections ◽

Igg Subclass ◽

Healthy Controls ◽

Serum Samples ◽

Igg Antibody ◽

Specific Antibodies

SummaryAn enzyme linked immunosorbent assay (ELISA), based on sheep hydatid cyst fluid antigen was used for the detection of specific antibodies of IgG, IgM, IgE and IgG subclass in the serum samples of 62 clinically and radiologically diagnosed cystic echinococcosis (CE) patients, 8 clinically suspected cases of CE, 25 other parasitic disease controls and 25 healthy controls. The diagnostic sensitivity in the clinically and radiologically suggestive cases (n = 62) for IgG antibody detection was highest (93 %), followed by IgE, IgG4, IgG1, IgG2, IgM and IgG3 with 89 %, 87 %, 85 %, 76 %, 70 % and 55 % respectively. The detection of specific IgE, IgG1 and IgG4 antibody showed the higher diagnostic sensitivity and specificity to the extent that they can be safely used as better substitute to IgG. Even though, the diagnostic sensitivity of IgG was highest (93%) but was less specific (88 %) due to the frequent non-specific reactions in the sera of patients with other parasitic infections and healthy controls. None of the sera samples from healthy controls gave non-specific reaction with IgE, IgG1 and IgG4 and there was a considerably reduced cross-reaction with these antibodies. The most discriminatory and specific antibodies found in this study belonged to IgE, IgG1 and IgG4; therefore, these antibodies may serve as useful diagnostic markers for CE.

Download Full-text

Serum microRNA signature is capable of predictive and prognostic factor for SARS-COV-2 virulence

Turkish Journal of Biochemistry ◽

10.1515/tjb-2020-0520 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Aydın Demiray ◽

Tuğba Sarı ◽

Ahmet Çalışkan ◽

Rukiye Nar ◽

Levent Aksoy ◽

...

Keyword(s):

Prognostic Factor ◽

Expression Profiles ◽

Healthy Controls ◽

Serum Samples ◽

Expression Levels ◽

Serum Microrna ◽

Transcriptional Gene Regulation ◽

Significant Expression ◽

Novel Concept ◽

Host Virus Interactions

Abstract Objectives Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MicroRNAs (miRNA) are small non-coding RNAs consisting of 19–25 nucleotides and play a role in post-transcriptional gene regulation. We have focused on serum expression levels of microRNA (miRNA) a novel concept of in host–virus interactions. MicroRNA expression profiles were investigated in serum samples of COVID-19 patients. Materials and methods The samples were collected from 40 patients diagnosed with COVID-19 patients and from 10 healthy controls. Expression profile of 20 miRNAs were examined using a quantitative real-time polymerase chain reaction (qPCR). Results Statistically significant expression level differences (p < 0.05) were detected in nine miRNAs in COVID-19 patients and healthy controls. 7 miRNAs (hsa-let-7d, hsa-miR-17, hsa-miR-34b, hsa-miR-93, hsa-miR-200b, hsa-miR-200c, hsa-miR-223) expression levels were found to be significantly decreased and the expression levels of 2 miRNAs (hsa-miR-190a and hsa-miR-203) significantly increased respect to healthy controls. Conclusions We expect that a miRNA profile can be beneficial for the diagnosis of the COVID-19. Our result revealed that the increase in hsa-miR-190a level may be a prognostic factor related to the COVID-19 disease.

Download Full-text

Soluble CD23 (sCD23): A Forgotten Indicator of Prognosis and Identifier of Outcome in Patients with Chronic Lymphocytic Leukemia Utilizing a Novel Cba Approach

Blood ◽

10.1182/blood.v124.21.1949.1949 ◽

2014 ◽

Vol 124 (21) ◽

pp. 1949-1949

Author(s):

Timothy William Farren ◽

Fengting Liu ◽

Magali Le Garff-Tavernier ◽

Marika Sarfati ◽

Frans Nauwelaers ◽

...

Keyword(s):

Chronic Lymphocytic Leukemia ◽

Complete Remission ◽

Risk Stratification ◽

Research Funding ◽

Response To Therapy ◽

Lymphocytic Leukemia ◽

Soluble Form ◽

Control Group ◽

Healthy Controls ◽

Serum Samples

Abstract Introduction: CD23 is a 45-kDa transmembrane glycoprotein corresponding to the low-affinity receptor for the immunoglobulin E (IgE). There are two isoforms - CD23a expressed on B-cells, and CD23b primarily expressed on monocytes, T-cells and platelets. The CD23 protein can be cleaved and released into the serum as a soluble form of CD23 (sCD23). The sCD23 is a 25kDa fragment that can be found in serum, plasma and urine in patients with chronic lymphocytic leukemia. Objective: To evaluate a novel and robust method of sCD23 detection using CBA detection, and correlate with known markers of prognostication and clinical outcome. Methods: At Barts & The London School of Medicine, historical serum samples have been taken at diagnosis from patients with CLL between 1984 to 2012 with corresponding clinical data. Serum analysis was obtained from 60 healthy controls and assessed for sCD23 in ng/ml (France and Canada). sCD23 levels (ng/ml) were evaluated against known prognostic markers and clinical features, including: ZAP-70 (>20%), CD38 (>20%), B2M, cytogenetics (17p-/11q- vs 12+/13q-/normal), LDH, splenomegaly, hepatomegaly, and lymphadenopathy. 107 samples from 86 patients underwent retrospective assessment of sCD23 from stored serum. The sCD23 cytometric bead array (CBA) flow cytometric assay (BD Biosciences) captures the soluble analyte with beads of known size and fluorescence.1 Capture beads are identified and sCD23 quantification (in ng/ml) is performed based on PE fluorescence excitation. Results were acquired using FACSDiva (BD Biosciences) and analysed using FCAParray. Statistical analysis was performed and significance was set at <0.05%. Results: sCD23 levels from the 86 patients ranged from 1.92 to 2441 ng/ml with a median value of 234.5 ng/ml. The sCD23 levels from the healthy control group ranged from 0.43 to 5.16 ng/ml with a median value of 1.56 ng/ml (figure 1). Figure 1: sCD23 levels between healthy controls and patients Figure 1:. sCD23 levels between healthy controls and patients Within the CLL patient cohort, elevated sCD23 significantly correlated with 6 out of the 8 prognostic & clinical indicators (Table 1). Table 1: Median sCD23 (ng/ml) for CLL patients by prognostic risk stratification. Indicator Median sCD23 (ng/ml) Level of significance (MWU-test) ZAP-70 positive (n=19) 1,096.0 P<0.01 ZAP-70 negative (n=38) 116.3 CD38 positive (n=22) 389.5 P=0.06 CD38 negative (n=50) 114.1 Poor risk karyotype (n=44) 580.7 P<0.01 Good risk karyotype (n=38) 135.8 B2M high (n=25) 116.9 P=0.95 B2M normal (n=16) 200.7 LDH high (n=31) 561.7 P=0.03 LDH normal (n=34) 140.6 Lymphadenopathy (n=50) 390.2 P<0.01 No lymphadenopathy (n=25) 40.80 Splenomegaly (n=30) 875.2 P<0.01 No splenomegaly (n=41) 73.60 Hepatomegaly (n=11) 425.8 P=0.04 Hepatomegaly (n=44) 110.2 In addition, there was a strong correlation with response to therapy. Those patients who never required therapy (n=21) had significantly lower levels of sCD23 (mean 93.36ng/ml) over those who achieved a partial remission (n=21, mean 650.2 ng/ml p<0.01), or those with no response to therapy (n=15, mean 1183.0 ng/ml, p<0.01). There was no difference between those with never required therapy and those who achieved a complete remission (n=14, mean 133.5ng/ml, p=0.70) (Figure 2). Figure 2: Mean sCD23 level (ng/ml) at diagnosis against response to therapy when required. Figure 2:. Mean sCD23 level (ng/ml) at diagnosis against response to therapy when required. Two patients had sequential serum samples taken throughout therapy. The patient with elevated sCD23 at diagnosis remained elevated through each treatment cycle to only achieve partial response, whilst the patient with low sCD23 at diagnosis responded well to therapy and achieved a complete remission (p=0.01, Figure 3). Figure 3: sCD23 following therapy. sCD23 non-responder did not respond to FC or FCR therapy . The responder received Chlorambucil+R then FCR. Figure 3:. sCD23 following therapy. sCD23 non-responder did not respond to FC or FCR therapy . The responder received Chlorambucil+R then FCR. Conclusion: We have evaluated in a pilot study the sCD23 CBA assay, which is an easy and reproducible assay. Elevated levels of sCD23 at diagnosis correlated with “physical” prognosis, as well as known biological markers of prognostication. Those patients with elevated levels of sCD23 at diagnosis correlated with response to therapy regardless of therapy given, and there is evidence that patients who do not respond to therapy retain their elevated levels of sCD23 during therapy. This simple assay could provide the basis for individualised risk stratification and prediction of response to therapy based on an individual analyte. Ref: 1 Grelier A et al. Cytometry B. 2014 Mar;86(2):91-7. Disclosures Farren: BD Biosciences: Research Funding. Nauwelaers:BD Biosciences: Employment. Keenan:BD Bioscience: Employment. Warner:BD Biosciences: Employment. Agrawal:BD Biosciences: Research Funding.

Download Full-text

Serum Metabolomics Study of Papillary Thyroid Carcinoma Based on HPLC-Q-TOF-MS/MS

Frontiers in Cell and Developmental Biology ◽

10.3389/fcell.2021.593510 ◽

2021 ◽

Vol 9 ◽

Author(s):

Yang Du ◽

Peizhi Fan ◽

Lianhong Zou ◽

Yu Jiang ◽

Xiaowen Gu ◽

...

Keyword(s):

Glutamic Acid ◽

Metabolic Pathways ◽

Acid Metabolism ◽

Methylmalonic Acid ◽

Partial Least Square ◽

Receiver Operating Curve ◽

Control Group ◽

Cancer Type ◽

Healthy Controls ◽

Serum Samples

This study examined metabolite profile differences between serum samples of thyroid papillary carcinoma (PTC) patients and healthy controls, aiming to identify candidate biomarkers and pathogenesis pathways in this cancer type. Serum samples were collected from PTC patients (n = 80) and healthy controls (n = 80). Using principal component analysis (PCA), partial least squares discrimination analysis(PLS-DA), orthogonal partial least square discriminant analysis (OPLS-DA), t-tests, and the volcano plot, a model of abnormal metabolic pathways in PTC was constructed. PCA, PLS-DA, and OPLS-DA analysis revealed differences in serum metabolic profiles between the PTC and control group. OPLS-Loading plot analysis, combined with Variable importance in the projection (VIP)>1, Fold change (FC) > 1.5, and p < 0.05 were used to screen 64 candidate metabolites. Among them, 22 metabolites, including proline betaine, taurocholic acid, L-phenylalanine, retinyl beta-glucuronide, alpha-tocotrienol, and threonine acid were upregulated in the PTC group; meanwhile, L-tyrosine, L-tryptophan, 2-arachidonylglycerol, citric acid, and other 42 metabolites were downregulated in this group. There were eight abnormal metabolic pathways related to the differential metabolites, which may be involved in the pathophysiology of PTC. Six metabolites yielded an area under the receiver operating curve of >0.75, specifically, 3-hydroxy-cis-5-tetradecenoylcarnitine, aspartylphenylalanine, l-kynurenine, methylmalonic acid, phenylalanylphenylalanine, and l-glutamic acid. The Warburg effect was observed in PTC. The levels of 3-hydroxy-cis-5-tetradecenoylcarnitine, aspartylphenylalanine, l-kynurenine, methylmalonic acid, phenylalanine, and L-glutamic acid may help distinguish PTC patients from healthy controls. Aspartic acid metabolism, glutamic acid metabolism, urea cycle, and tricarboxylic acid cycle are involved in the mechanism of PTC.

Download Full-text

Performance of the commercially available SERION ELISA classic Echinococcus IgG test for the detection of cystic echinococcosis in clinical practice

Journal of Helminthology ◽

10.1017/s0022149x18000536 ◽

2018 ◽

Vol 93 (05) ◽

pp. 636-639 ◽

Cited By ~ 2

Author(s):

M.J. Sarink ◽

R. Koelewijn ◽

B.C.G.C. Slingerland ◽

A.G.M. Tielens ◽

P.J.J. van Genderen ◽

...

Keyword(s):

Cystic Echinococcosis ◽

Clinical Performance ◽

Imaging Techniques ◽

Healthy Controls ◽

Imaging Studies ◽

Serum Samples ◽

Predictive Values ◽

Complementary Role ◽

Negative Controls ◽

Positive Results

AbstractDiagnosis of cystic echinococcosis (CE) is at present mainly based on imaging techniques. Serology has a complementary role, partly due to the small number of standardized and commercially available assays. Therefore we examined the clinical performance of the SERION ELISA classic Echinococcus IgG test. Using 10 U/ml as a cut-off point, and serum samples from 50 CE patients and 105 healthy controls, the sensitivity and specificity were 98.0% and 96.2%, respectively. If patients with other infectious diseases were used as negative controls, the specificity decreased to 76.9%, which causes poor positive predictive values. However, if results between 10 and 15 U/ml are classified as indecisive, the specificity of positive results (≥15 U/ml) increased to 92.5% without greatly affecting the sensitivity (92.0%). Using this approach in combination with imaging studies, the SERION ELISA classic Echinococcosis IgG test can be a useful aid in the diagnosis of CE.

Download Full-text